drugset
drugset / Trial / NCT00762112

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762112 ↗

Phase 3 Terminated 316 enrolled Takeda
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to determine the long-term safety of TAK-559, once daily (QD), in subjects with Type 2 Diabetes.

Timeline

Start
2003-11
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IMIGLITAZAR Small molecule 32 mg Oral

Indications

diabetes mellitus